Peoples Financial Services CORP. Has $3.57 Million Stock Position in AbbVie Inc. (NYSE:ABBV)

Peoples Financial Services CORP. lessened its holdings in AbbVie Inc. (NYSE:ABBVFree Report) by 1.5% during the second quarter, reports. The firm owned 26,487 shares of the company’s stock after selling 417 shares during the period. AbbVie accounts for 1.6% of Peoples Financial Services CORP.’s portfolio, making the stock its 14th biggest position. Peoples Financial Services CORP.’s holdings in AbbVie were worth $3,569,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the business. Castle Rock Wealth Management LLC lifted its stake in AbbVie by 5.7% in the second quarter. Castle Rock Wealth Management LLC now owns 3,578 shares of the company’s stock valued at $492,000 after acquiring an additional 194 shares during the last quarter. Mechanics Bank Trust Department raised its holdings in shares of AbbVie by 9.0% in the 2nd quarter. Mechanics Bank Trust Department now owns 11,111 shares of the company’s stock valued at $1,497,000 after purchasing an additional 920 shares during the period. Good Life Advisors LLC grew its holdings in AbbVie by 13.5% during the second quarter. Good Life Advisors LLC now owns 22,837 shares of the company’s stock worth $3,077,000 after purchasing an additional 2,721 shares during the period. Sanders Morris Harris LLC increased its position in AbbVie by 541.9% during the second quarter. Sanders Morris Harris LLC now owns 23,096 shares of the company’s stock worth $3,117,000 after buying an additional 19,498 shares during the last quarter. Finally, Trinity Legacy Partners LLC raised its stake in AbbVie by 1.0% in the second quarter. Trinity Legacy Partners LLC now owns 29,317 shares of the company’s stock valued at $3,950,000 after buying an additional 283 shares during the period. Institutional investors and hedge funds own 67.86% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ABBV. HSBC started coverage on AbbVie in a report on Friday, July 14th. They set a “buy” rating and a $167.00 price target for the company. Piper Sandler raised their target price on shares of AbbVie from $163.00 to $170.00 and gave the stock an “overweight” rating in a research note on Friday, July 28th. Credit Suisse Group decreased their price target on shares of AbbVie from $170.00 to $160.00 in a research note on Wednesday, July 12th. William Blair began coverage on AbbVie in a report on Tuesday, July 25th. They set a “market perform” rating for the company. Finally, TheStreet upgraded AbbVie from a “c+” rating to a “b” rating in a research note on Monday, August 28th. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $165.79.

Get Our Latest Stock Report on ABBV

AbbVie Stock Down 1.0 %

Shares of ABBV opened at $152.12 on Monday. The company has a debt-to-equity ratio of 4.33, a quick ratio of 0.77 and a current ratio of 0.89. AbbVie Inc. has a 52 week low of $130.96 and a 52 week high of $168.11. The stock has a market capitalization of $268.50 billion, a price-to-earnings ratio of 31.30, a PEG ratio of 2.74 and a beta of 0.58. The stock has a fifty day moving average of $146.42 and a 200-day moving average of $147.44.

AbbVie (NYSE:ABBVGet Free Report) last announced its quarterly earnings results on Thursday, July 27th. The company reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.79 by $0.12. AbbVie had a return on equity of 151.29% and a net margin of 15.50%. The firm had revenue of $13.87 billion for the quarter, compared to analyst estimates of $13.52 billion. As a group, sell-side analysts anticipate that AbbVie Inc. will post 11.03 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be issued a $1.48 dividend. This represents a $5.92 annualized dividend and a yield of 3.89%. The ex-dividend date is Thursday, October 12th. AbbVie’s payout ratio is presently 121.81%.

Insiders Place Their Bets

In other news, CEO Richard A. Gonzalez sold 18,500 shares of the stock in a transaction on Monday, July 31st. The shares were sold at an average price of $149.15, for a total transaction of $2,759,275.00. Following the completion of the sale, the chief executive officer now directly owns 625,294 shares in the company, valued at $93,262,600.10. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.26% of the company’s stock.

About AbbVie

(Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.

Recommended Stories

Want to see what other hedge funds are holding ABBV? Visit to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBVFree Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with's FREE daily email newsletter.